Progressive Supranuclear Palsy — Research Summary
Printed from RareWays (rareways.com.au) on 11 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Automated differentiation of parkinsonian disorders: an ROI-based analysis of subcortical shape and cortical surface features.
Dehghan Yousef et al. — Cognitive neurodynamics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41647139/
- 2.
REM sleep behavior disorder as a shared motor phenotype: A multidimensional clinical study.
Lanza Giuseppe et al. — Sleep medicine (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41780439/
- 3.
Polygonatum Sibiricum polysaccharide ameliorates Alzheimer's disease by alleviating cuproptosis and activating the PI3K/AKT signaling pathway.
Wang Shuping et al. — Journal of ethnopharmacology (10 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41687942/
- 4.
Impact of preference signaling and geographic preferencing on research productivity and regional matching in orthopaedic surgery residency.
Ali Iyad S et al. — American journal of surgery (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41713185/
- 5.
Reply to the Letter to the Editor regarding "Clinical implications of progressive ventilatory impairment in multiple system atrophy and progressive supranuclear palsy".
Okubo So et al. — Journal of the neurological sciences (15 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41759418/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Completed — Phase 2 — Allon Therapeutics
https://clinicaltrials.gov/study/NCT01110720
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Progressive Supranuclear Palsy
Progressive Supranuclear Palsy is a rare brain disease that causes degeneration of cells in the brainstem and cerebral cortex. It is frequently misdiagnosed as Parkinson's disease. Key features include falls, eye movement abnormalities, stiffness, and cognitive changes. There is no disease-modifying treatment and median survival after diagnosis is 6-7 years.
Most Recent Research
UNLABELLED: The clinical manifestations of early-stage parkinsonian syndromes overlap, making accurate differential diagnosis crucial yet challenging. This study aimed to develop a system for automated differentiation of idiopathic Parkinson's disease (IPD) from progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Our sample included clinical data and T1-weighted magnetic resonance imaging from 50 IPD, 47 PSP, and 38 CBS patients. We introduced an atlas-based approach to extract shape features from subcortical regions in each subject's native coordinate image space. The surface thickness and folding parameters were also extracted from cortical regions. A statistical analysis was conducted to identify regions with significant differences in the extracted features, followed by the employment of a feed-forward neural network to distinguish these patients. Significant structural differences were observed in several regions, including the thalamic nuclei, basal ganglia, midbrain, cerebellum, cingulate cortex, and insula. Using only cortical surface features, our diagnostic model outperformed the model that relied solely on subcortical shape features. However, the classifier achieved its best predictive performance when incorporating features from both cortical and subcortical structures, yielding an accuracy of 86.1% in a multi-class classification system and 96.1% for distinguishing IPD from PSP and CBS, as well as an accuracy of 94.2% for classifying CBS versus PSP in a two-class classification system. Our findings underscore the significance of cortical morphological patterns and demonstrate that the proposed methodology could potentially serve as an automated diagnostic system in clinical settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11571-025-10402-2.
Common Questions
What is Progressive Supranuclear Palsy?
Progressive Supranuclear Palsy is a rare brain disease that causes degeneration of cells in the brainstem and cerebral cortex. It is frequently misdiagnosed as Parkinson's disease. Key features include falls, eye movement abnormalities, stiffness, and cognitive changes. There is no disease-modifying treatment and median survival after diagnosis is 6-7 years.
How many clinical trials are available for Progressive Supranuclear Palsy?
RareWays currently indexes 143 clinical trials for Progressive Supranuclear Palsy, of which 30 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Progressive Supranuclear Palsy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Progressive Supranuclear Palsy.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.